Swiss National Bank Signals Increased Willingness for FX Market Intervention
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Should l Buy NOV?
Source: CNBC
- Increased Intervention Willingness: The Swiss National Bank (SNB) has indicated a heightened willingness to intervene in the foreign exchange market due to the Middle East conflict, aiming to counter rapid appreciation of the Swiss franc and safeguard price stability, reflecting its commitment to economic stability.
- Interest Rate Held Steady: The SNB announced it would maintain its key interest rate at 0%, despite rising inflation risks, indicating a cautious approach to monetary policy to avoid reverting to negative rates that were in place until 2022.
- Foreign Exchange Market Dynamics: As geopolitical tensions rise, demand for the Swiss franc as a safe-haven asset increases, potentially leading to sustained appreciation pressures, prompting the SNB to consider foreign exchange interventions to maintain economic stability.
- Tense Trade Relations: Switzerland's trade relationship with the U.S. is strained due to tariff issues, necessitating the SNB to balance foreign exchange market interventions with the risk of provoking further disputes with the U.S., highlighting the complexity and challenges of its policy decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NOV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NOV
Wall Street analysts forecast NOV stock price to rise
11 Analyst Rating
5 Buy
5 Hold
1 Sell
Moderate Buy
Current: 18.560
Low
16.00
Averages
19.18
High
23.00
Current: 18.560
Low
16.00
Averages
19.18
High
23.00
About NOV
NOV Inc. is an independent provider of equipment and technology to the upstream oil and gas industry. The Company's proprietary technology portfolio supports the industry’s drilling, completion, and production needs. It operates under two segments: Energy Products and Services, and Energy Equipment. The Company’s Energy Products and Services segment primarily designs, manufactures, rents, and sells products and equipment used in drilling, intervention, completion, and production activities. Its products include drill bits, downhole tools, premium drill pipe, drilling fluids, managed pressure drilling, integral and weld-on connectors for conductor strings and surface casing, completion tools, and artificial lift systems. Its Energy Equipment segment manufactures and supports the capital equipment and integrated systems needed for oil and gas exploration and production, both onshore and offshore, as well as for other marine-based, industrial and renewable energy markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Iran War Triggers Heavy Selling in European Equity Markets
- Market Sell-Off Pressure: The outbreak of the Iran war has led to significant selling pressure across European equity markets in March, with the UK's FTSE 100 down 5%, while Germany's DAX and France's CAC 40 both fell by 7%, reflecting investor concerns over a second energy price shock in four years.
- Swiss Market Performance: The Swiss Market Index dropped 7.5% in March, hitting a low of approximately 13% down on March 20 before recovering some losses as the conflict evolved, with analysts suggesting that the Swiss equity market is well-positioned for a potential sentiment rebound.
- UBS Analyst Insights: UBS analysts highlighted that Swiss equities, trading at around 16x forward earnings with a 3.2% dividend yield, are now more appealing compared to Swiss franc bonds offering zero interest, prompting an upgrade of Swiss equities to
See More
Novartis Plans $2 Billion Acquisition of Excellergy for Allergy Treatment
- Acquisition Strategy: Novartis is planning to acquire U.S.-based biotech Excellergy for up to $2 billion, aiming to enhance its allergy drug portfolio by introducing the early-stage candidate Exl-111, which is expected to outperform existing market treatments in speed and efficacy.
- Patent Expiration Response: This acquisition represents Novartis' latest bolt-on deal to counteract looming patent expirations, particularly as its best-selling drugs face generic competition, which is anticipated to positively impact future revenue streams.
- Recent Transaction Activity: Prior to the Excellergy deal, Novartis announced the acquisition of Pikavation Therapeutics for up to $3 billion to secure rights to an experimental breast cancer drug, highlighting its strategic focus on oncology.
- Market Reaction: While Novartis shares traded sideways in morning trading in Zurich, they have increased by 33% over the past year, reflecting market confidence in its acquisition strategy and future growth potential.
See More
NOV Inc. Invests $200M to Double Subsea Pipe Capacity in Brazil
- Capacity Expansion Plan: NOV Inc. announced a $200M investment to roughly double the capacity of its subsea flexible pipe manufacturing facility in Açu, Brazil, over the next three years to support anticipated long-term demand growth.
- Market Demand Forecast: The company indicated that its current manufacturing capacity is operating at or near full utilization, with a backlog extending into 2028, highlighting the potential for increased offshore development activity.
- Industry Trend Analysis: NOV President and CEO Jose Bayardo emphasized that without the additional capacity planned to come online by late 2029, the industry's current capacity will likely be insufficient to meet demand into the 2030s.
- Customer Support: An executive from Brazilian customer Petrobras stated that as the world's largest consumer of subsea flexible pipe, they support NOV's investment in Brazil, which enhances local manufacturing capabilities.
See More
Merck Acquires Terns Pharmaceuticals for $6.7 Billion
- Acquisition Scale: Merck announced its acquisition of Terns Pharmaceuticals for $53 per share in cash, totaling approximately $6.7 billion, which represents a 6% premium over Tuesday's closing price, aimed at bolstering its portfolio ahead of Keytruda's patent expiration in 2028.
- Positive Market Reaction: Following the announcement, Terns' stock rose 5.3% in premarket trading and surged as much as 15% earlier in the day, indicating strong investor enthusiasm for its potential drug and reflecting positive market sentiment regarding the deal.
- Strategic Importance: This acquisition marks Merck's third multibillion-dollar purchase in the past year, highlighting the company's proactive strategy to expand its oncology investments in anticipation of potential revenue declines following Keytruda's patent expiration.
- Drug Development Outlook: Terns is developing a drug for a specific type of leukemia, which analysts believe could become a multibillion-dollar competitor, potentially rivaling Novartis' Scemblix, thereby enhancing Merck's position in the biopharmaceutical sector.
See More
NOV to Expand Manufacturing Facility in Brazil
- Capacity Expansion Plan: NOV plans to invest $200 million over the next three years to nearly double the capacity of its subsea flexible pipe manufacturing facility in Açu, Brazil, to meet anticipated demand from deepwater developments and ensure competitiveness in the 2030s.
- Demand-Driven Market: The current facility operates at near-full capacity with a backlog extending into 2028, indicating sustained growth in demand for subsea flexible pipes, and NOV's expansion will effectively alleviate future supply-demand imbalances.
- Introduction of Technological Innovations: This expansion will enable NOV to introduce new technologies, including CO₂-resistant subsea flexible pipes designed for high-CO₂ applications, which is expected to further expand the market and enhance the company's competitiveness in high-end applications.
- Collaboration with Petrobras: Petrobras supports NOV's investment, believing it will enhance local manufacturing capacity and help achieve offshore production targets, further solidifying NOV's position as a trusted long-term partner.
See More
RPT-NOV INC - CAPITAL EXPENDITURE PLAN FOR 2026 TO RISE BY $50 MILLION
- Capital Expenditure Increase: The capital expenditure plan is set to increase by $50 million.
- Future Investments: This increase indicates a commitment to future investments and development initiatives.
See More
Iran War Triggers Heavy Selling in European Equity Markets
- Market Sell-Off Pressure: The outbreak of the Iran war has led to significant selling pressure across European equity markets in March, with the UK's FTSE 100 down 5%, while Germany's DAX and France's CAC 40 both fell by 7%, reflecting investor concerns over a second energy price shock in four years.
- Swiss Market Performance: The Swiss Market Index dropped 7.5% in March, hitting a low of approximately 13% down on March 20 before recovering some losses as the conflict evolved, with analysts suggesting that the Swiss equity market is well-positioned for a potential sentiment rebound.
- UBS Analyst Insights: UBS analysts highlighted that Swiss equities, trading at around 16x forward earnings with a 3.2% dividend yield, are now more appealing compared to Swiss franc bonds offering zero interest, prompting an upgrade of Swiss equities to
See More
Novartis Plans $2 Billion Acquisition of Excellergy for Allergy Treatment
- Acquisition Strategy: Novartis is planning to acquire U.S.-based biotech Excellergy for up to $2 billion, aiming to enhance its allergy drug portfolio by introducing the early-stage candidate Exl-111, which is expected to outperform existing market treatments in speed and efficacy.
- Patent Expiration Response: This acquisition represents Novartis' latest bolt-on deal to counteract looming patent expirations, particularly as its best-selling drugs face generic competition, which is anticipated to positively impact future revenue streams.
- Recent Transaction Activity: Prior to the Excellergy deal, Novartis announced the acquisition of Pikavation Therapeutics for up to $3 billion to secure rights to an experimental breast cancer drug, highlighting its strategic focus on oncology.
- Market Reaction: While Novartis shares traded sideways in morning trading in Zurich, they have increased by 33% over the past year, reflecting market confidence in its acquisition strategy and future growth potential.
See More
NOV Inc. Invests $200M to Double Subsea Pipe Capacity in Brazil
- Capacity Expansion Plan: NOV Inc. announced a $200M investment to roughly double the capacity of its subsea flexible pipe manufacturing facility in Açu, Brazil, over the next three years to support anticipated long-term demand growth.
- Market Demand Forecast: The company indicated that its current manufacturing capacity is operating at or near full utilization, with a backlog extending into 2028, highlighting the potential for increased offshore development activity.
- Industry Trend Analysis: NOV President and CEO Jose Bayardo emphasized that without the additional capacity planned to come online by late 2029, the industry's current capacity will likely be insufficient to meet demand into the 2030s.
- Customer Support: An executive from Brazilian customer Petrobras stated that as the world's largest consumer of subsea flexible pipe, they support NOV's investment in Brazil, which enhances local manufacturing capabilities.
See More
Merck Acquires Terns Pharmaceuticals for $6.7 Billion
- Acquisition Scale: Merck announced its acquisition of Terns Pharmaceuticals for $53 per share in cash, totaling approximately $6.7 billion, which represents a 6% premium over Tuesday's closing price, aimed at bolstering its portfolio ahead of Keytruda's patent expiration in 2028.
- Positive Market Reaction: Following the announcement, Terns' stock rose 5.3% in premarket trading and surged as much as 15% earlier in the day, indicating strong investor enthusiasm for its potential drug and reflecting positive market sentiment regarding the deal.
- Strategic Importance: This acquisition marks Merck's third multibillion-dollar purchase in the past year, highlighting the company's proactive strategy to expand its oncology investments in anticipation of potential revenue declines following Keytruda's patent expiration.
- Drug Development Outlook: Terns is developing a drug for a specific type of leukemia, which analysts believe could become a multibillion-dollar competitor, potentially rivaling Novartis' Scemblix, thereby enhancing Merck's position in the biopharmaceutical sector.
See More
NOV to Expand Manufacturing Facility in Brazil
- Capacity Expansion Plan: NOV plans to invest $200 million over the next three years to nearly double the capacity of its subsea flexible pipe manufacturing facility in Açu, Brazil, to meet anticipated demand from deepwater developments and ensure competitiveness in the 2030s.
- Demand-Driven Market: The current facility operates at near-full capacity with a backlog extending into 2028, indicating sustained growth in demand for subsea flexible pipes, and NOV's expansion will effectively alleviate future supply-demand imbalances.
- Introduction of Technological Innovations: This expansion will enable NOV to introduce new technologies, including CO₂-resistant subsea flexible pipes designed for high-CO₂ applications, which is expected to further expand the market and enhance the company's competitiveness in high-end applications.
- Collaboration with Petrobras: Petrobras supports NOV's investment, believing it will enhance local manufacturing capacity and help achieve offshore production targets, further solidifying NOV's position as a trusted long-term partner.
See More
RPT-NOV INC - CAPITAL EXPENDITURE PLAN FOR 2026 TO RISE BY $50 MILLION
- Capital Expenditure Increase: The capital expenditure plan is set to increase by $50 million.
- Future Investments: This increase indicates a commitment to future investments and development initiatives.
See More
